Ciolfi C, Tartaglia J, Alaibac M. Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?
Antibodies (Basel) 2024;
13:4. [PMID:
38247568 PMCID:
PMC10801591 DOI:
10.3390/antib13010004]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 10/12/2023] [Accepted: 01/02/2024] [Indexed: 01/23/2024] Open
Abstract
Rituximab is currently approved for patients affected by moderate-to-severe pemphigus vulgaris, a severe autoimmune blistering skin disease that can be life-threatening. The standard rituximab dosing regimens, originally established for B-cell non-Hodgkin's lymphomas, have been recognized to exceed the effective dose required for inducing B-cell depletion, considering that the B-cell burden in pemphigus vulgaris is considerably lower than in lymphoproliferative disorders. We herein report our experience with very ultra-low-dose rituximab in two patients affected by pemphigus vulgaris.
Collapse